Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Japan Added as Mogamulizumab PIII Study Site for CTCL Patients: Kyowa Kirin
January 16, 2014
- Takeda to Sell BIKEN Varicella Vaccine from February
January 16, 2014
- Swiss Novartis to “Fully Address” Flaws Leading to Criminal Complaint Filing
January 16, 2014
- Seikagaku Confirms Winning in Gel-One Patent Infringement Lawsuit Following Genzyme’s Withdrawal of Appeal
January 16, 2014
- Special Drug Use-Result Survey for Plavix Finds 0.19% Incidence of Cerebral Hemorrhage in Cerebral Infarction in Acute Phase
January 16, 2014
- Takeda Appoints Former GSK Exec as Head of CNS Drug Discovery Unit
January 15, 2014
- Shionogi Inc., Hisamitsu Unit to Copromote Hot Flashes Drug in US
January 15, 2014
- Daiichi Sankyo, 2 US Startups to Collaborate on Research of Academia-Oriented Seeds
January 14, 2014
- Ethical Drug Sales Up 0.8% in November Due to New Drug Launches and Lifting of 14-Day Prescription Limit: Crecon Report
January 14, 2014
- Pharma Biz Leaders Say New Price Cut Rule for Long-Listed Products a Painful Blow
January 10, 2014
- Daiichi Sankyo Submits NDA for Edoxaban in US
January 10, 2014
- Novartis Issues Apologies after Complaint Filing over Diovan, Vows Cooperation with Authorities
January 10, 2014
- Proposal to Reduce Basic Fees for Medical Institutions with Low Price Agreement Rates Could Have Big Impact: Mr Kono of Toho Pharmaceutical
January 10, 2014
- New IFN-Free Oral Drugs for Chronic Hepatitis C Could Create New Market
January 10, 2014
- MTPC Sets Up Medway Business Management Office Eyeing Resumption of Medway Injection Production
January 9, 2014
- Baxter Seeks Japan Approval of Recombinant Factor IX for Hemophilia B
January 9, 2014
- Takeda Initiates PIII Trials of Vedolizumab in Japan; Filing Expected in FY2017
January 9, 2014
- Daiichi Sankyo Applies for European Approval of Edoxaban
January 9, 2014
- Former Pfizer EPBU Head Matsumori Joins SBI Biotech as President
January 8, 2014
- Astellas Ties Up with ClearPath in US to Invest in RSV Vaccine Development
January 8, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…